An observational study in Healthy Adult and Sleep Apnea, sponsored by Ouraring Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Ouraring Inc. · Observational
Among 369 studies in Sleep Apnea Syndromes with a site in United States — 49 open to participants now, 60 under way, 3 of them phase 3. Sleep Apnea Syndromes · United States.
Among the 369 studies in Sleep Apnea Syndromes with a site in United States, this one is the 53rd largest by planned enrollment of the 82 observational ones, is one of 15 that started in 2026, is one of 82 observational ones, reaches primary completion later than 10 of the 59 other live ones, and was the 366th registered.
1,084 studies on the registry are indexed under Sleep Apnea Syndromes; 171 are open to participants now.
This study's planned enrollment of 60 is below the median of 150 across 343 observational studies indexed under Sleep Apnea Syndromes.
Browse Sleep Apnea Syndromes studies →49 of the 369 studies in Sleep Apnea Syndromes with a site in United States are open now, in 3 countries. Each count lists the studies.
Of the 117 Sleep Apnea Syndromes studies recruiting now, 57 (49%) set no upper age limit and 36 (31%) stop at 75 or younger; 24 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →369 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 15 started in 2026.
Median enrollment 62 across the 284 interventional studies, 114 across the 82 observational. Of the 268 that completed or were terminated, 134 (50%) have results posted.
82 of 369 have an industry lead sponsor. The 10 most frequent:
Ouraring Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Ouraring Inc. has 1 study filed under Sleep Apnea Syndromes — fewer than ten, so there is no comparison to draw.
29 of the studies in Sleep Apnea Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382754Children's Hospital of PhiladelphiaHome Apnea Testing in CHildren Trial | 2026-12 |
| NCT05575401Loma Linda UniversityLateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy | 2026-12 |
| NCT02431507Michael HarrisonMagnetic Apnea Prevention(MAGNAP) Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety | 2026-12-01 |
| NCT07908199Ouraring Inc.Oura Ring OA15 Validation | 2026-12-03 |
| NCT03278119NYU Langone HealthSleep Aging and Risk for Alzheimer's 2.0 | 2026-12-25 |
Among the 369 studies in Sleep Apnea Syndromes with a site in United States, from their registry updates:
The current study intends to collect data from Oura Ring time-locked to ground truth medical sleep diagnostic gold-standard polysomnography (PSG) for product research and development, investigational algorithm validation, and scientific dissemination.
The study population will be composed of adults in the general population in the St. Louis area, including patients from the clinic database and general community.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy sample
Inclusion Criteria:
Exclusion Criteria:
Sleep Apnea sample Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adults with no known sleep disorders
High risk for mild-to-severe sleep apnea, defined by at least one of the following: 1. Prior clinical diagnosis of obstructive sleep apnea (OSA) 2. Currently seeking or actively undergoing treatment for sleep apnea (e.g., PAP therapy, oral appliance) 3. Documented apnea-hypopnea index (AHI) ≥5 events/hour from a previous sleep study
Sleep staging performance (co-primary endpoint)
Agreement between Oura Ring sleep stage output and adjudicated PSG sleep stage scoring across the overnight in-laboratory recording (quantified by overall accuracy, Cohen's kappa, and class-specific sensitivity, specificity, positive predictive value, and F1 score for Wake, REM, and NREM sleep).
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Signal quality performance (co-primary endpoint)
Signal-to-noise ratio for overnight SpO2 signal quality.
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Respiratory event detection performance - apnea events
Event-level detection of PSG-scored apnea events by Oura Ring, quantified by sensitivity, positive predictive value, false positive rate per hour, and F1 score.
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Respiratory event detection performance - hypopnea events
Event-level detection of PSG-scored hypopnea events by Oura Ring, quantified by sensitivity, positive predictive value, false positive rate per hour, and F1 score.
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Respiratory event detection performance - oxygen desaturation events
Event-level detection of PSG-scored oxygen desaturation events by Oura Ring, quantified by sensitivity, positive predictive value, false positive rate per hour, and F1 score.
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Overnight SpO2 agreement
Agreement between Oura Ring overnight oxygen saturation estimates and PSG reference SpO2 measurements over matched overnight intervals, which may be quantified by mean bias, mean absolute error, root mean squared error, correlation, and Bland-Altman limits of agreement.
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Overnight heart rate and HRV agreement
Agreement between Oura Ring overnight heart rate and heart rate variability estimates and ECG-derived reference metrics over matched overnight intervals, which may be quantified by mean bias, mean absolute error, root mean squared error, correlation, and Bland-Altman limits of agreement.
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Data completion (proportion of overnight recording time)
Proportion of intended overnight recording time yielding valid Oura outputs (across sleep staging, heart rate, heart rate variability, SpO2, and Sleep Apnea Risk).
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Data completion (proportion of participants with complete datasets)
Proportion of participants contributing analyzable data for all Oura outputs (sleep staging, heart rate, heart rate variability, SpO2, and sleep apnea risk).
Time frame: Single time-point assessment post-overnight-PSG visit (baseline).
Plan to share: No — IPD will not be shared as part of this study.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.